<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04150744</url>
  </required_header>
  <id_info>
    <org_study_id>1102320191018</org_study_id>
    <nct_id>NCT04150744</nct_id>
  </id_info>
  <brief_title>RFA Plus Carrizumab vs Carrizumab Alone for HCC</brief_title>
  <official_title>Radiofrequency Ablation Plus Carrizumab vs Carrizumab Alone for Moderate or Advanced Hepatocellular Carcinoma: A Real World Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to find whether patients with advanced HCC can get more benefits from RFA
      +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the
      result of PFS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to find whether patients with advanced HCC can get more benefits from RFA
      +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the
      result of PFS. 120 patients were enrolled into two groups respectively, the experimental
      group and reference group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>through study completion, an average of 4 years</time_frame>
    <description>Time from patients received treatment fist time to disease progress or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>through study completion, an average of 4 years</time_frame>
    <description>The ratio of patients with regressive disease ,including complete response and partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>through study completion, an average of 4 years</time_frame>
    <description>The ratio of patients with regressive or stable disease, including complete response, partial response and stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>through study completion, an average of 4 years</time_frame>
    <description>Time from the random assignment to death (the last follow-up time for patients lost to follow-up, the end of study for patients still alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>through study completion, an average of 4 years</time_frame>
    <description>Time from the first time of complete regression or partial regression to progressive disease or death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Tumor Immunity</condition>
  <condition>Immunosuppression</condition>
  <condition>Radiofrequency Ablation</condition>
  <arm_group>
    <arm_group_label>RFA plus carrizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>carrizumab</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
    <description>take advantage of RFA to destroy hepatocellular carcinoma by high temperature</description>
    <arm_group_label>RFA plus carrizumab</arm_group_label>
    <arm_group_label>carrizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age from 18-75 years

          2. Diagnosis as hepatocellular carcinoma from histology and cytology

          3. BCLC B-C degree

          4. Score of ECOG PS: 0-2

          5. Child-Pugh Score: A or B

          6. Not suitable for resection or liver transplantation

          7. Have not received systemic therapy

          8. Have at least one evaluable target mass from CT or MRI according to mRECIST

          9. The estimated survival time ≥ 12 weeks

         10. Patients with HBV infection having HBV-DNA &lt;500IU/mL and standard anti-virus
             treatment. Patients with HCV infection must receive standard anti-virus treatment.

         11. The function of main organs normal

         12. Sign informed consent

        Exclusion Criteria:

          1. Have cholangiocarcinoma, mixed type of hepatocarcinoma and fibrolamellar
             hepatocellular carcinoma. Have incurable malignant tumor in five years.

          2. Have local ablation, TACE or radiotherapy in 3 months before enrolled.

          3. Prepared to or have received organic or bone marrow transplantation.

          4. Uncontrollable ascites, hepatic encephalopathy or esophageal and gastric varices.

          5. Have hypertension and can't lower down to the normal level using blood pressure
             medication.

          6. Have type II myocardial ischemia or myocardial infarction, uncontrollable arrhythmia.

          7. Have diseases to influent the effect of oral drugs, for example, unable to swallow,
             chronic diarrhea and intestinal obstruction.

          8. Have gastrointestinal bleeding in 6 months

          9. Have abdominal fistula, gastrointestinal perforation or abdominal abscess

         10. Patients with lung fibrosis, interstitial pneumonia, pneumoconiosis, radiation
             pneumonitis, drug related pneumonia or severe dysfunction of lung.

         11. Routine urine test showed urinary protein ≥++ or the 24 hours amount of urinary
             protein ≥1.0 g

         12. Patients have autoimmune disease

         13. Patients need corticosteroid or other immunosuppressant therapy

         14. Patients have anti-tumor vaccine and other immunostimulate anti-tumor drugs in 3
             months

         15. Allergy to monocloning antibody

         16. Pregnant or breastfeeding female Other patients not suitable to be enrolled in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhe Tang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhe Tang, Dr.</last_name>
    <phone>13757118212</phone>
    <email>8xi@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>the Second Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhe Tang, Dr.</last_name>
      <phone>13757118212</phone>
      <email>8xi@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>November 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RFA</keyword>
  <keyword>immunosuppressant</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

